Analyst Reco. Neurocrine Biosciences, Inc.

Equities

NBIX

US64125C1099

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-12 EDT			5-day change	1st Jan Change
134.6 ^USD	+1.10%		+0.70%	+2.17%

06-05	Transcript : Neurocrine Biosciences, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 02:30 PM
06-03	Neurocrine Biosciences, Inc. Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Neurocrine Biosciences Insider Sold Shares Worth $5,338,565, According to a Recent SEC Filing	05-31	MT
UBS Raises Price Target on Neurocrine Biosciences to $193 From $174, Maintains Buy Rating	05-28	MT
Neurocrine Biosciences Insider Sold Shares Worth $297,860, According to a Recent SEC Filing	05-21	MT
Neurocrine Biosciences Insider Sold Shares Worth $4,138,436, According to a Recent SEC Filing	05-16	MT
UBS Raises Price Target on Neurocrine Biosciences to $174 From $165, Maintains Buy Rating	05-02	MT
Oppenheimer Adjusts Neurocrine Biosciences Price Target to $216 From $200, Maintains Outperform Rating	05-02	MT
Wells Fargo Upgrades Neurocrine Biosciences to Overweight From Equalweight, Price Target is $170	04-24	MT
Morgan Stanley Lifts Price Target on Neurocrine Biosciences to $160 From $150, Sees Upside to Shares Ahead of Mid-Stage Readouts; Overweight Kept	04-08	MT
JPMorgan Adjusts Price Target on Neurocrine Biosciences to $158 From $148, Maintains Overweight Rating	03-20	MT
Oppenheimer Adjusts Neurocrine Biosciences Price Target to $200 From $170, Maintains Outperform Rating	03-13	MT
UBS Adjusts Price Target on Neurocrine Biosciences to $159 From $128, Maintains Buy Rating	02-20	MT
Deutsche Bank Raises Neurocrine Biosciences Price Target to $161 From $160, Maintains Buy Rating	02-08	MT
Citigroup Trims Price Target on Neurocrine Biosciences to $140 From $141, Maintains Neutral Rating	02-08	MT
Mizuho Securities Raises Price Target on Neurocrine Biosciences to $140 From $116, Maintains Neutral Rating	02-08	MT
Wells Fargo Raises Price Target on Neurocrine Biosciences to $140 From $127, Maintains Equalweight Rating	02-08	MT
Wedbush Adjusts Neurocrine Biosciences' Price Target to $147 From $141, Keeps Outperform Rating	01-29	MT
Goldman Sachs Raises Price Target on Neurocrine Biosciences to $153 From $134, Maintains Buy Rating	01-25	MT
Barclays Raises Neurocrine Biosciences' Price Target to $150 From $145, Maintains Overweight Rating	01-23	MT
RBC Raises Price Target on Neurocrine Biosciences to $129 From $121, Keeps Sector Perform Rating	01-03	MT
Stifel Adjusts Price Target on Neurocrine Biosciences to $144 From $141, Maintains Buy Rating	12-18	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Neurocrine Biosciences, Inc.

Equities

NBIX

US64125C1099

Analyst Reco.

Filters